These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9722733)

  • 1. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
    Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
    Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
    Zouboulis CC; Treudler R; Orfanos CE
    Hautarzt; 1993 Jul; 44(7):440-5. PubMed ID: 8365878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
    Alpsoy E; Durusoy C; Yilmaz E; Ozgurel Y; Ermis O; Yazar S; Basaran E
    Arch Dermatol; 2002 Apr; 138(4):467-71. PubMed ID: 11939808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
    Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
    Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alfa-2a in the treatment of Behçet's disease.
    Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
    Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of interferon alpha in Behçet disease: review of the literature.
    Kötter I; Günaydin I; Zierhut M; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):320-35. PubMed ID: 15079763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
    Krause L; Altenburg A; Pleyer U; Köhler AK; Zouboulis CC; Foerster MH
    J Rheumatol; 2008 May; 35(5):896-903. PubMed ID: 18412306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches in the treatment of Adamantiades-Behçet's disease.
    Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C
    Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy for Behçet's disease.
    Alpsoy E; Yilmaz E; Başaran E
    J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.
    Georgiou S; Monastirli A; Pasmatzi E; Gartaganis S; Goerz G; Tsambaos D
    J Intern Med; 1998 May; 243(5):367-72. PubMed ID: 9651559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic interferon alpha 2b treatment in Behçet's syndrome.
    Hamuryudan V; Moral F; Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Direskeneli H; Akoglu T; Yazici H
    J Rheumatol; 1994 Jun; 21(6):1098-100. PubMed ID: 7932420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
    Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
    Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
    Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
    Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
    Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
    Demiroglu H; Ozcebe OI; Barista I; Dündar S; Eldem B
    Lancet; 2000 Feb; 355(9204):605-9. PubMed ID: 10696980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease.
    Adler YD; Mansmann U; Zouboulis CC
    Dermatology; 2001; 203(4):322-4. PubMed ID: 11752821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)].
    Sánchez Román J; Pulido Aguilera MC; Castillo Palma MJ; Ocaña Medina C; Toral Peña A; López-Checa F; Wichmann I
    Rev Clin Esp; 1996 May; 196(5):293-8. PubMed ID: 8768028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.